Combination of Cardonizumab Injection and TKI Second Line Therapy for Advanced Hepatocellular Cancer

This study tests whether combining two immunotherapy drugs (cardonizumab, a PD-1 blocker) with a targeted blood vessel drug (TKI) is effective for people with advanced liver cancer (hepatocellular carcinoma) who have already tried at least one other treatment. **You may be eligible if...** - You have confirmed hepatocellular carcinoma (the most common type of liver cancer) - You are between 18 and 75 years old - Your cancer is advanced or cannot be surgically removed - You have already tried at least one systemic (whole-body) cancer treatment and it stopped working - You have at least one measurable tumor - Your liver and overall health are within acceptable ranges - Your ECOG performance score is 0 or 1 (able to carry out normal activity) **You may NOT be eligible if...** - Your liver is too weak to handle treatment - You have not tried any prior treatment - You have serious other health conditions Talk to your doctor to see if this trial is right for you.